TY - JOUR
T1 - Correction to: Combining GLP-1 Receptor Agonists and Basal Insulin in Older Adults with Type 2 Diabetes: Focus on Lixisenatide and Insulin Glargine (Advances in Therapy, (2019), 36, 12, (3321-3339), 10.1007/s12325-019-01126-x)
AU - Handelsman, Yehuda
AU - Muskiet, Marcel H. A.
AU - Meneilly, Graydon S.
N1 - Publisher Copyright: © 2019, The Author(s). Copyright: Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2019
Y1 - 2019
N2 - On page 3331 of the original article, the word, ‘‘/LYXUMIA’’ has been removed from the section RATIONALE FOR COMBINATION THERAPY COMPRISING GLP-1 RAs AND BASAL INSULIN and the associated reference, numbered 100, has been corrected to: Xultophy® (insulin degludec/liraglutide) [summary of product characteristics]. Bagsvaerd, Denmark: Novo Nordisk A/S https://www.ema.europa.eu/ en/documents/product-information/xultophyepar- product-information_en.pdf. Accessed November 2019.
AB - On page 3331 of the original article, the word, ‘‘/LYXUMIA’’ has been removed from the section RATIONALE FOR COMBINATION THERAPY COMPRISING GLP-1 RAs AND BASAL INSULIN and the associated reference, numbered 100, has been corrected to: Xultophy® (insulin degludec/liraglutide) [summary of product characteristics]. Bagsvaerd, Denmark: Novo Nordisk A/S https://www.ema.europa.eu/ en/documents/product-information/xultophyepar- product-information_en.pdf. Accessed November 2019.
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85076924683&origin=inward
UR - https://www.ncbi.nlm.nih.gov/pubmed/31873867
UR - http://www.scopus.com/inward/record.url?scp=85076924683&partnerID=8YFLogxK
U2 - https://doi.org/10.1007/s12325-019-01185-0
DO - https://doi.org/10.1007/s12325-019-01185-0
M3 - Erratum/Corrigendum
C2 - 31873867
SN - 0741-238X
VL - 37
SP - 973
JO - Advances in therapy
JF - Advances in therapy
IS - 2
ER -